Stockscreener 앱 받기
3.77
0.53%
-0.02
시간 외 거래:
3.81
0.04
+1.06%
전일 마감가:
$3.79
열려 있는:
$3.81
하루 거래량:
888.10K
Relative Volume:
0.42
시가총액:
$287.64M
수익:
$80.00M
순이익/손실:
$-76.12M
주가수익비율:
-3.2883
EPS:
-1.1465
순현금흐름:
$-63.88M
1주 성능:
-0.79%
1개월 성능:
-1.82%
6개월 성능:
-49.26%
1년 성능:
-48.50%
1일 변동 폭
$3.755
$3.82
1주일 범위
$3.75
$3.85
52주 변동 폭
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.77 | 289.93M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inv - The National Law Review
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ... - pmg-ky3.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to an Ongoing Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inves - The National Law Review
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse - kalkine.ca
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - The National Law Review
Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - Kalkine Media
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse - kalkine.ca
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan
Fulcrum (NASDAQ: FULC) plans special cash dividend ahead of Slate Medicines merger - Stock Titan
Kaplan Fox Initiates Securities Probe Into Fulcrum Therapeutics Following 51% Stock Plunge - Kalkine Media
Fulcrum Therapeutics faces securities probe aft... - Pluang
Fulcrum Therapeutics Inc. (FULC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - The Globe and Mail
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Programme Discontinuation Triggers 51% Stock Drop - kalkine.ca
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance
Fulcrum (FULC) Close: Ends Up by 0.26% at $3.84; Chart View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionVolatility Smile - vinanet.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Fulcrum Therapeutics Stock Drops 51% After Pociredir Discontinuation Triggers Securities Investigation - kalkine.ca
Fulcrum (FULC) Stock: Falls 0.52% to $3.83 at the Close; Chart View: Support at $3.64 and Resistance at $4.02 Frame the Range in the Latest SessionAnalyst Upgrade Stocks - vinanet.vn
Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEarnings Revision Report - vinanet.vn
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire
Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Slate Medicines to Merge With Fulcrum Therapeutics - Cooley
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger - Legal Desire
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement with Key Financial Details - Kalkine Media
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com
What's Going On With Fulcrum Therapeutics Stock Monday?Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field - AllSci
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies - Yahoo Finance
Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate - The Business Journals
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Plunge - kalkine.ca
Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics and Slate Medicines to merge, refocusing combined company on migraine pipeline - The Pharma Letter
Fulcrum Therapeutics stock rises on Slate Medicines merger deal By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock rises on Slate Medicines merger deal - Investing.com
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations - The National Law Review
Fulcrum to merge with Slate in all-stock deal after drug setback - Reuters
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
자본화:
|
볼륨(24시간):